Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Adenocarcinoma of Esophagogastric Junction.”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04202484
What this trial is testing

Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer
RenJi Hospital 20
Testing effectiveness (Phase 2)Study completedNCT01077999
What this trial is testing

Chemoradiation and Panitumumab for Esophageal Cancer

Who this might be right for
Squamous Cell CarcinomaAdenocarcinomaEsophageal Cancer+1 more
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 78
Testing effectiveness (Phase 2)Active Not RecruitingNCT04152499
What this trial is testing

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Who this might be right for
Epithelial Ovarian CancerGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma+7 more
Klus Pharma Inc. 1,410
Not applicableNot Yet RecruitingNCT07493382
What this trial is testing

Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adenocarcinoma: A Single-Arm, Phase II Study of Safety and Efficacy

Who this might be right for
GEJ Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT06196697
What this trial is testing

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Harbin Medical University 50
Early research (Phase 1)Ended earlyNCT02952989
What this trial is testing

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

Who this might be right for
Carcinoma, Non-Small-Cell LungCarcinoma, Renal CellBreast Neoplasms+5 more
Seagen Inc. 47
Early research (Phase 1)Study completedNCT02443324
What this trial is testing

Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Who this might be right for
Gastric AdenocarcinomaAdenocarcinoma of the Gastroesophageal JunctionNon-small Cell Lung Cancer+2 more
Eli Lilly and Company 175
Testing effectiveness (Phase 2)UnknownNCT06266871
What this trial is testing

SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
West China Hospital 64
Post-approval studies (Phase 4)Not Yet RecruitingNCT07161453
What this trial is testing

Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology

Who this might be right for
Gastric / Gastroesophageal Junction Adenocarcinoma
Liaoning Cancer Hospital & Institute 500
Not applicableUnknownNCT05649163
What this trial is testing

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

Who this might be right for
HER2Advanced Gastric CancerAdvanced Gastroesophageal Junction Adenocarcinoma+1 more
Shen Lin 306
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06933966
What this trial is testing

Evaluation of Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma

Who this might be right for
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal CarcinomaNon Metastatic Disease
Centre Leon Berard 120
Not applicableUnknownNCT04675866
What this trial is testing

Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer

Who this might be right for
Advanced Gastric Adenocarcinoma
Henan Cancer Hospital 46
Testing effectiveness (Phase 2)Study completedNCT02514551
What this trial is testing

Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Eli Lilly and Company 245
Early research (Phase 1)UnknownNCT03071042
What this trial is testing

A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma

Who this might be right for
Metastatic Gastric Adenocarcinoma
Sir Run Run Shaw Hospital 12
Early research (Phase 1)Not Yet RecruitingNCT07807956
What this trial is testing

Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsNon-Small Cell Lung CancerColorectal Cancer+6 more
AbbVie 130
Large-scale testing (Phase 3)Looking for participantsNCT07643623
What this trial is testing

Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. 720
Large-scale testing (Phase 3)Looking for participantsNCT06123494
What this trial is testing

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

Who this might be right for
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd. 360
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06241469
What this trial is testing

Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study

Who this might be right for
Gastric CancerGastroEsophageal CancerAdenocarcinoma
Wu Jun 40
Testing effectiveness (Phase 2)UnknownNCT04263870
What this trial is testing

Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Who this might be right for
Gastroesophageal Junction AdenocarcinomaStomach AdenocarcinomaLocally Advanced Unresectable Gastric Adenocarcinoma+1 more
Sichuan University 36
Large-scale testing (Phase 3)Study completedNCT02178956
What this trial is testing

BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Sumitomo Pharma America, Inc. 714
Next Page